Skip to main content

Advertisement

Articles

Page 24 of 24

  1. Amplification of the ERBB2 (Her-2/neu) oncogene, which occurs in approximately 25% of breast carcinomas, is a known negative prognostic factor. Available data indicate that a variable number of nearby genes on ch...

    Authors: Lydia Usha, Bita Tabesh, Larry E Morrison, Ruta D Rao, Kris Jacobson, April Zhu, Sanjib Basu and John S Coon

    Citation: Journal of Hematology & Oncology 2008 1:12

    Content type: Research

    Published on:

  2. In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical on...

    Authors: David Chu and Shenhong Wu

    Citation: Journal of Hematology & Oncology 2008 1:11

    Content type: Review

    Published on:

  3. Molecular characterisation of normal karyotype acute myeloid leukemia (NK-AML) allows prognostic stratification and potentially can alter treatment choices and pathways. Approximately 45–60% of patients with N...

    Authors: Angela YC Tan, David A Westerman, Dennis A Carney, John F Seymour, Surender Juneja and Alexander Dobrovic

    Citation: Journal of Hematology & Oncology 2008 1:10

    Content type: Short report

    Published on:

  4. Previous studies demonstrated Ganoderma lucidum polysaccharides (GL-PS), a form of bioactive β-glucan can stimulate the maturation of monocyte-derived dendritic cells (DC). The question of how leukemic cells espe...

    Authors: Wing Keung Chan, Christopher Ching Hang Cheung, Helen Ka Wai Law, Yu Lung Lau and Godfrey Chi Fung Chan

    Citation: Journal of Hematology & Oncology 2008 1:9

    Content type: Research

    Published on:

  5. In a departure from conventional strategies to improve treatment outcome for myeloid malignancies, we report the isolation of leukemia-specific peptides using a phage display library screened with freshly obta...

    Authors: Naomi Galili, Emmanuelle Devemy and Azra Raza

    Citation: Journal of Hematology & Oncology 2008 1:8

    Content type: Research

    Published on:

  6. To report the clinico-histopathologic features, management and outcome of Rosai-Dorfman disease of the orbit.

    Authors: Geeta K Vemuganti, Milind N Naik and Santosh G Honavar

    Citation: Journal of Hematology & Oncology 2008 1:7

    Content type: Research

    Published on:

  7. Histone deacetylase (HDAC) inhibitors are a new class of chemotherapeutic agents. Our laboratory has recently reported that phenylhexyl isothiocyanate (PHI), a synthetic isothiocyanate, is an inhibitor of HDAC...

    Authors: Quanyi Lu, Xianghua Lin, Jean Feng, Xiangmin Zhao, Ruth Gallagher, Marietta Y Lee, Jen-Wei Chiao and Delong Liu

    Citation: Journal of Hematology & Oncology 2008 1:6

    Content type: Research

    Published on:

  8. Lipoic acid (LA), a potent antioxidant, has been used as a dietary supplement to prevent and treat many diseases, including stroke, diabetes, neurodegenerative and hepatic disorders. Recently, potent anti-tumo...

    Authors: Elangovan Selvakumar and Tze-chen Hsieh

    Citation: Journal of Hematology & Oncology 2008 1:4

    Content type: Research

    Published on:

  9. Detection of circulating tumor cells (CTC) in the blood of cancer patients may have prognostic and predictive significance. However, background expression of 'tumor specific markers' in peripheral blood mononu...

    Authors: Fanglei You, Lisa A Roberts, S Peter Kang, Raquel A Nunes, Cinara Dias, J Dirk Iglehart, Natalie A Solomon, Paula N Friedman and Lyndsay N Harris

    Citation: Journal of Hematology & Oncology 2008 1:2

    Content type: Research

    Published on:

Annual Journal Metrics

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here

Advertisement